Gyre Therapeutics, Inc. (L9S.F)

13.20 +0.30 (+2.33%) At close: 08:06AM CEST

Gyre Therapeutics, Inc.

12770 High Bluff Drive
Suite 150
San Diego, CA 92130
United States
619-949-3681
https://www.gyretx.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 593

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Han Ying Ph.D.	CEO & Director	9.75k	N/A	1966
Mr. Songjiang Ma	President & Director	N/A	N/A	1956
Ms. Ruoyu Chen	Chief Financial Officer	112.67k	N/A	1971
Mr. Weiguo Ye	Chief Operating Officer	254.96k	N/A	1978

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis. In addition, its development pipeline includes F573, under Phase 2 studies for the treatment of acute/acute-on-chronic liver failure; F528, under preclinical stage for the treatment of chronic obstructive pulmonary disease; and F230, under preclinical stage for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.

Corporate Governance

Gyre Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.